JP2018510898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510898A5 JP2018510898A5 JP2017553076A JP2017553076A JP2018510898A5 JP 2018510898 A5 JP2018510898 A5 JP 2018510898A5 JP 2017553076 A JP2017553076 A JP 2017553076A JP 2017553076 A JP2017553076 A JP 2017553076A JP 2018510898 A5 JP2018510898 A5 JP 2018510898A5
- Authority
- JP
- Japan
- Prior art keywords
- amisulpride
- unit dose
- antiemetic
- kit
- acute phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506116.1A GB201506116D0 (en) | 2015-04-10 | 2015-04-10 | Kit and combination therapy for nausea and vomiting |
| GB1506116.1 | 2015-04-10 | ||
| PCT/GB2016/050998 WO2016162695A1 (en) | 2015-04-10 | 2016-04-11 | Combinations of amisulpride and another anti-emetic for treating nausea and vomiting |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510898A JP2018510898A (ja) | 2018-04-19 |
| JP2018510898A5 true JP2018510898A5 (enExample) | 2019-04-18 |
| JP6812360B2 JP6812360B2 (ja) | 2021-01-13 |
Family
ID=53333601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553076A Active JP6812360B2 (ja) | 2015-04-10 | 2016-04-11 | 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10322106B2 (enExample) |
| EP (1) | EP3280392B1 (enExample) |
| JP (1) | JP6812360B2 (enExample) |
| KR (2) | KR102711661B1 (enExample) |
| CN (1) | CN107872975A (enExample) |
| AU (1) | AU2016246104B2 (enExample) |
| CA (1) | CA2982251C (enExample) |
| CY (1) | CY1124184T1 (enExample) |
| DK (1) | DK3280392T3 (enExample) |
| ES (1) | ES2866933T3 (enExample) |
| GB (1) | GB201506116D0 (enExample) |
| HR (1) | HRP20210624T1 (enExample) |
| HU (1) | HUE054165T2 (enExample) |
| IL (2) | IL295650A (enExample) |
| LT (1) | LT3280392T (enExample) |
| MX (1) | MX388735B (enExample) |
| PL (1) | PL3280392T3 (enExample) |
| PT (1) | PT3280392T (enExample) |
| RS (1) | RS61760B1 (enExample) |
| SI (1) | SI3280392T1 (enExample) |
| SM (1) | SMT202100216T1 (enExample) |
| WO (1) | WO2016162695A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| CA3142355A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| JP2025510741A (ja) | 2022-03-21 | 2025-04-15 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| EP4638455A1 (en) | 2022-12-22 | 2025-10-29 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2026501285A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| JP2026526054A (ja) | 2023-07-13 | 2026-08-04 | アコンカグア・バイオ・インコーポレイテッド | 化合物、組成物、および方法 |
| EP4743174A1 (en) | 2023-07-13 | 2026-05-20 | Aconcagua Bio, Inc. | CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS |
| EP4771001A1 (en) | 2023-08-31 | 2026-07-08 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026041075A1 (en) | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| WO2026051998A1 (en) | 2024-09-04 | 2026-03-12 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2026096926A1 (en) | 2024-11-01 | 2026-05-07 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2026156091A1 (en) | 2025-01-15 | 2026-07-23 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003962D0 (en) | 2010-03-10 | 2010-04-21 | Tangentix Ltd | Multimedia content delivery system |
| GB201004020D0 (en) * | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| WO2013040164A1 (en) * | 2011-09-13 | 2013-03-21 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating metabolic disorders |
-
2015
- 2015-04-10 GB GBGB1506116.1A patent/GB201506116D0/en not_active Ceased
-
2016
- 2016-04-11 RS RS20210407A patent/RS61760B1/sr unknown
- 2016-04-11 KR KR1020177032393A patent/KR102711661B1/ko active Active
- 2016-04-11 CN CN201680030994.9A patent/CN107872975A/zh active Pending
- 2016-04-11 EP EP16716659.4A patent/EP3280392B1/en active Active
- 2016-04-11 AU AU2016246104A patent/AU2016246104B2/en active Active
- 2016-04-11 HR HRP20210624TT patent/HRP20210624T1/hr unknown
- 2016-04-11 KR KR1020247026775A patent/KR20240125705A/ko active Pending
- 2016-04-11 IL IL295650A patent/IL295650A/en unknown
- 2016-04-11 HU HUE16716659A patent/HUE054165T2/hu unknown
- 2016-04-11 JP JP2017553076A patent/JP6812360B2/ja active Active
- 2016-04-11 PT PT167166594T patent/PT3280392T/pt unknown
- 2016-04-11 ES ES16716659T patent/ES2866933T3/es active Active
- 2016-04-11 MX MX2017012991A patent/MX388735B/es unknown
- 2016-04-11 WO PCT/GB2016/050998 patent/WO2016162695A1/en not_active Ceased
- 2016-04-11 SI SI201631183T patent/SI3280392T1/sl unknown
- 2016-04-11 PL PL16716659T patent/PL3280392T3/pl unknown
- 2016-04-11 DK DK16716659.4T patent/DK3280392T3/da active
- 2016-04-11 CA CA2982251A patent/CA2982251C/en active Active
- 2016-04-11 SM SM20210216T patent/SMT202100216T1/it unknown
- 2016-04-11 US US15/565,479 patent/US10322106B2/en active Active
- 2016-04-11 LT LTEP16716659.4T patent/LT3280392T/lt unknown
-
2017
- 2017-10-08 IL IL254929A patent/IL254929A0/en unknown
-
2021
- 2021-05-20 CY CY20211100442T patent/CY1124184T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102711661B1 (ko) | 구역과 구토를 치료하기 위한 아미설프리드 및 추가의 구토 방지제의 병용 | |
| JP2023541432A5 (enExample) | ||
| JP2023541430A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| HRP20180301T1 (hr) | Postupci liječenja psorijaze uporabom il-17 antagonista | |
| JP2016532516A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2019511506A5 (enExample) | ||
| JP2024501919A5 (enExample) | ||
| JP2018138596A5 (enExample) | ||
| JP2016515137A5 (enExample) | ||
| FI3590960T3 (fi) | Perifeeristen hermojen IgG-stimuloitu remyelinaatio | |
| JP2022550828A5 (enExample) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2014508174A5 (enExample) | ||
| JP2015510945A5 (enExample) | ||
| SI2686002T1 (en) | A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| JP2016533856A5 (enExample) | ||
| JP2013542262A5 (enExample) | ||
| WO2016077565A3 (en) | Methods for chronic pain management and treatment using hcg | |
| JP2017530142A5 (enExample) | ||
| JP2017515849A5 (enExample) | ||
| PE20252784A1 (es) | Composiciones y metodos para administrar paltusotina a pacientes con insuficiencia hepatica |